$IMMU News

Last published 4mo ago

4mo agoIMMUApproval of Trodelvy, Bla #761115FDA Approved DrugsApproval Date: 06/24/2026; Drug Name: Trodelvy, Bla #761115; Active Ingredients: SACITUZUMAB GOVITECAN-HZIY; Company: Immunomedics Inc; Submission Status: Approval; Application Number: 761115
2y agoFREQ URGN VYGR SCMP+1NorthStar Appoints Peter Pfreundschuh to Board of ManagersBusiness WireNorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer
3y agoIMMUImmunomedics, Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
4y agoIMMUSEC Charges Pharma CFO and Former Partner with Insider TradingSEC Press ReleasesThe Securities and Exchange Commission today charged the former Chief Financial Officer of pharmaceutical company Immunomedics, Inc. and his former romantic partner with insider trading in the company’s stock. According to the SEC’s complaint,…
5y agoIMMUImmunomedics, Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
5y agoIMMUNew patent application published for: Biomarkers for Antibody-Drug Conjugate Monotherapy or Combination TherapyUS Patent Applications (USPTO)( 1 of 1 )
5y agoIMMUTesting Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases - NCT04647916ClinicalTrials.govObjective response rate (ORR), Overall survival, Progression-free survival, Incidence of adverse events
6y agoIMMUA Phase 1, Dose Escalation Study in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment - NCT04617522ClinicalTrials.govCmax, AUC
6y agoGILD IMMUGilead Sciences Completes Acquisition of Immunomedics, Inc.Business WireFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate.
6y agoIMMUSacituzumab Govitecan in Primary HER2-negative Breast Cancer - NCT04595565ClinicalTrials.govInvasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice., To compare overall survival (OS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice., Distant disease-free survival (DDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice., (and 8 more...)
6y agoIMMUProteoNic Announces Licensing of Technology for Production of Biologics to ImmunomedicsPR NewswireProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G...
6y agoIMMUImmunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric GlioblastomaGlobeNewswireMORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoIMMU MR MOBLMoore Kuehn Encourages IMMU, MOBL, MR, and SCBH Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
6y agoIMMUImmunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial CancerGlobeNewswireTrodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC) sBLA submission for accelerated...
6y agoIMMUTrodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast CancerGlobeNewswireTrodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemotherapy Trodelvy is the...
6y agoIMMUImmunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain CancersGlobeNewswireMORRIS PLAINS, N.J., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoNNVC IMMU GILD INO+1Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVIDPR NewswireThe National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update...
6y agoIMMU ONDK VRTU OTELMoore Kuehn Encourages IMMU, ONDK, VRTU, and OTEL Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
6y agoAGEN RCUS CGEN SGEN+5Gilead and Merck’s Billion Dollar Bets Face Tests as Ink DriesBloombergGilead Sciences Inc. and Merck & Co.’s big bets on emerging cancer-fighting technologies will have an opportunity to show their worth at a highly anticipated cancer conference, just days after announcing their deals.
6y agoPFE GILD IMMU MSFT+1Asia Stocks Look Set to Drift; Dollar Weakens: Markets WrapBloombergAsian stocks looked poised to drift Tuesday after snapping two weeks of declines Monday. U.S. shares rose for a second day amid a flurry of deal activity, while the dollar weakened.
6y agoIMMU ORCL NVDA DAL+7Stocks making the biggest moves midday: Oracle, Nvidia, Immunomedics, Overstock & moreCNBCOracle, Nvidia and Immunomedics were all up on dealmaking news. Overstock got a boost after an analyst upgrade.
6y agoIMMU TMUS ORCL VZ+1This Merger Monday Is Nothing to Cheer AboutBloombergNone of the $60-plus billion in announced deals necessarily signals renewed bullishness toward the economy, and in fact, one is flashing just the opposite.
6y agoORCL MSFT IMMU GILDDealmakers Clinch $68 Billion of M&A in Year’s Busiest WeekendBloombergA blockbuster Sunday of takeovers has bled into Monday for the fastest start to a week for global dealmaking so far this year.
6y agoGILD IMMUGilead CEO: We're studying new ways to treat coronavirus with remdesivir outside of the hospitalCNBC"We want to follow the science here. We don't to get ahead of it," Gilead Sciences CEO Daniel O'Day told CNBC on Monday.
6y agoNVDA IMMU GILD ORCL+10Stocks making the biggest moves premarket: Nvidia, Oracle, Immunomedics, Delta, Nikola & moreCNBCNvidia, Oracle and Immunomedics all surged on dealmaking activity. Delta backs new debt with its frequent flyer program.
6y agoDAL UAL AAL AAPL+85 things to know before the stock market opens MondayCNBCHeading into Monday trading, the Nasdaq was off just under 10% from its closing record on Sept. 2.
6y agoGILD IMMU SGENMerck Inks Up to $4.5 Billion Seattle Genetics Cancer DealBloombergMerck & Co. plans to take an equity stake and pay as much as $4.5 billion in a series of deals with Seattle Genetics Inc. for two of its cancer drugs.
6y agoORCL IMMU GILD PFEU.S. Stock Futures Rise on Reports Related to Vaccines, DealsBloombergU.S. stock index futures rose in Asia as reports related to coronavirus treatments and corporate acquisitions supported investor sentiment ahead of the Federal Reserve’s policy meeting this week.
6y agoGILD IMMUGilead Sciences to Acquire ImmunomedicsBusiness WireFOSTER CITY, Calif. & MORRIS PLAINS, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gile ...
6y agoIMMUImmunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020GlobeNewswireBreadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy™ in brain tumors Conference call and webcast with key...
6y agoIMMUImmunomedics to Participate in Upcoming Healthcare ConferencesGlobeNewswireMORRIS PLAINS, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoAZN IMMU ONCY MRK+1Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 ExpressionsPR NewswireUSA News Group – In the fight against some of the most challenging forms of cancer, AstraZeneca PLC (NYSE:AZN) recently placed a giant $6 billion bet ...
6y agoIMMUNew patent granted for: Antibody-Sn-38 Immunoconjugates with a Cl2a LinkerUS Patent Applications (USPTO)
6y agoIMMUImmunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™GlobeNewswireMORRIS PLAINS, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoIMMUImmunomedics Reports Second Quarter 2020 Results and Provides Corporate UpdateGlobeNewswireEncouraging early adoption of Trodelvy™ in U.S. with $20.1M net sales in first two months of launch Confirmatory Phase 3 ASCENT study met primary endpoint of progression-free survival and key...
6y agoIMMUImmunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020GlobeNewswireMORRIS PLAINS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoONCY IMMU INCY AZNNew Drug Developments and Combinations Aiding Badly Neglected Triple-Negative Breast Cancer PatientsPR NewswireUSA News Group – A recent study from the National Comprehensive Cancer Center (NCCN) delivered a shocking indictment of the oncology field as a...
6y agoIMMUNew patent granted for: Efficacy of Anti-Hla-Dr Antibody Drug Conjugate Immu-140 (hl243-Cl2a-Sn-38) in Hla-Dr Positive CancersUS Patent Applications (USPTO)
6y agoIMMUImmunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung CancersGlobeNewswireCompanies have ongoing collaboration in first-line metastatic triple-negative breast cancer Immunomedics also announces Phase 2 NeoSTAR study in neoadjuvant triple-negative breast cancer has begun...
6y agoD BRK.A UBER SPOT+6Stocks making the biggest moves midday: Uber, Spotify, Tesla, Dominion Energy, Zoom Video & moreCNBCUber shares get a boost on news of a deal with Postmates. Spotify falls on an analyst downgrade.
6y agoIMMUImmunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)GlobeNewswireTrodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy...
6y agoIMMUImmunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical UpdateGlobeNewswireMORRIS PLAINS, N.J., July 02, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoIMMUImmunomedics to Participate in Upcoming Healthcare ConferencesGlobeNewswireMORRIS PLAINS, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoIMMUImmunomedics Announces Leadership Change and Provides Business Update Amid COVID-19GlobeNewswireMORRIS PLAINS, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoIMMUNew patent granted for: Antibody-Drug Conjugates and Uses ThereofUS Patent Applications (USPTO)
6y agoIMMUImmunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual MeetingGlobeNewswireMORRIS PLAINS, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoIMMUImmunomedics' (IMMU) Management on Q1 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoIMMUImmunomedics Reports First Quarter 2020 Results and Provides Corporate UpdateGlobeNewswireTrodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch ASCENT study...
6y agoIMMUImmunomedics Announces Commercial Availability of TRODELVY™ in the United StatesGlobeNewswireMORRIS PLAINS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
6y agoIMMUImmunomedics Announces Closing Of Public Offering Of Common StockGlobeNewswireMORRIS PLAINS, N.J., May 01, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...